UK Authorization for Aflibercept   - Scorecard - MDSpire

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min

Share

Clinical Scorecard: UK Authorization for Aflibercept

At a Glance

CategoryDetail
ConditionVisual impairment due to macular edema secondary to retinal vein occlusion (RVO)
Key MechanismsAnti-VEGF therapy
Target PopulationTreatment-naïve patients with RVO
Care SettingOphthalmology clinics

Key Highlights

  • Aflibercept 8 mg approved for RVO treatment in the UK
  • Based on Phase III QUASAR trial data
  • 8 mg formulation shows non-inferior visual acuity gains compared to 2 mg
  • Patients on 8 mg require fewer injections over time
  • Durability of treatment intervals improved with 8 mg regimen

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of RVO confirmed through clinical examination and imaging

Management

  • Initiate treatment with aflibercept 8 mg after diagnosis

Monitoring & Follow-up

  • Regular assessment of visual acuity and anatomical outcomes

Risks

  • Monitor for potential adverse effects consistent with anti-VEGF therapy

Patient & Prescribing Data

Patients with visual impairment due to RVO

Aflibercept 8 mg may reduce treatment burden while maintaining efficacy

Clinical Best Practices

  • Consider higher-dose aflibercept for patients requiring intensive early treatment
  • Evaluate treatment intervals based on patient response and fluid reduction

References

Original Source(s)

UK Authorization for Aflibercept  

  • March 3, 2026

Related Content

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it. 

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.